All In Biotech

Drug Trial Radar · NCT05608681

A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE).

A Phase 1b/2 Trial Evaluating the Safety, Pharmacokinetics, and Efficacy of EP-104GI in Adults With Eosinophilic Esophagitis (RESOLVE)

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 117 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

117

Planned (sponsor's estimate)

Start

Mar 31, 2023

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Eupraxia Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Nov 8, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 1b/2 study to explore the safety, efficacy and pharmacokinetics of EP-104GI in adults with eosinophilic esophagitis (EoE). Endoscopic and histologic assessments will also be evaluated to understand the local effects of EP-104GI on eosinophilic EoE disease activity. Approximately 27 to 33 participants will be enrolled in dose escalation: 3-6 participants per dose cohort. The number of participants enrolled in escalation will depend on the number of dose escalation cohorts evaluated, and dose cohorts needing to be expanded. An additional 10-24 participants will be enrolled in 1 or 2 cohorts of 10-12 participants each at tolerable dose regimen(s) selected based on the accumulated clinical data to identify the recommended phase 2 dose(s) (RP2D). In the Phase 2 randomized dose optimization portion of the study, approximately 120 subjects will be randomized to Dose A (120 mg total dose), Dose B (160 mg total dose), or matching vehicle control, with an overall assignment ratio of 1:1:1. The total number of participants in both portions of the study will be approximately 160. The study involves 8-10 site visits spread over approximately 52 weeks. Participants in an extended PK sub study will have up to 4 additional visits, to a maximum of 108 weeks post-dose. The participants will either receive the active study drug (EP-104GI) or matching vehicle control. Matching vehicle control will be used only in randomized dose optimization portion of the study. Participants randomized to receive vehicle control may receive EP-104GI (Dose A or Dose B) following the completion of Week 24 providing they meet eligibility criteria for crossover to EP-104GI. Participants randomized to receive EP-104GI on Day 0 will not receive EP-104GI or vehicle control at Week 24. The study drug or matching vehicle control will be administered by qualified personnel during an esophagogastroduodenoscopy (EGD) procedure at the Baseline/Dosing visit. Safety will be assessed throughout the study. Blood and urine samples will be collected at site visits for laboratory assessments and to measure plasma levels of EP-104GI. Participants will complete questionnaires to assess symptoms of dysphagia and odynophagia and will undergo 3-5 EGDs with esophageal biopsies at the Baseline, Week 4 (dose escalation phase only), Week 12, Week 24 (randomized dose optimization phase only), Week 26, and Week 52 (randomized dose optimization phase only).

Conditions

  • Eosinophilic Esophagitis

Interventions

  • EP-104GIDrug

    Extended-release fluticasone propionate \[FP\] for injectable suspension for gastrointestinal administration, Powder suspended in vehicle

  • Matching vehicle controlOther

    A sterile liquid containing sterile water and excipients necessary to prepare a uniform suspension of the powder.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Escalation- Incidence of treatment emergent adverse events (TEAEs)Time frame: 52 weeks
  2. Dose Escalation- Severity of treatment emergent adverse events (TEAEs)Time frame: 52 weeks
  3. Dose Escalation- Change from baseline in morning serum cortisol levelsTime frame: 52 weeks
  4. Dose Escalation- Plasma concentrations of fluticasone propionateTime frame: 108 weeks
  5. Dose Escalation- Change from baseline in physical examination results, BMI and weight change.Time frame: 12 weeks
  6. Randomised Dose Optimization- Change from baseline in EoEHSS grade and stage scored in 3 regions of the esophagus within the injection area (proximal, mid, distal)Time frame: 24 weeks

Locations

33 sites in 6 countries. Site status is shown where the registry gives one.

  • Campbelltown Private Hospital

    Sydney, New South Wales, Australia · Recruiting

  • Mater Hospital Brisbane

    Brisbane, Queensland, Australia · Active not recruiting

  • Princess Alexandra Hospital

    Brisbane, Queensland, Australia · Recruiting

  • Coastal Digestive Health

    Maroochydore, Queensland, Australia · Recruiting

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia · Recruiting

  • Lyell McEwin Hospital

    Elizabeth Vale, South Australia, Australia · Recruiting

  • Tennyson Centre Day Hospital

    Kurralta Park, South Australia, Australia · Recruiting

  • Eastern Health Box Hill

    Box Hill, Victoria, Australia · Recruiting

  • Northern Hospital Epping

    Epping, Victoria, Australia · Recruiting

  • The Alfred Hospital

    Melbourne, Victoria, Australia · Recruiting

  • Royal Melbourne Hospital

    Parkville, Victoria, Australia · Recruiting

  • St John of God Midland

    Midland, Washington, Australia · Recruiting

  • University of Calgary

    Calgary, Alberta, Canada · Recruiting

  • South Edmonton Gastroenterology Research Clinic

    Edmonton, Alberta, Canada · Recruiting

  • G.I. Research Institute

    Vancouver, British Columbia, Canada · Recruiting

  • Brampton Gastroenterology Research Group Inc.

    Brampton, Ontario, Canada · Recruiting

  • Charlton Digestive Disease Centre

    Hamilton, Ontario, Canada · Active not recruiting

  • McMaster University

    Hamilton, Ontario, Canada · Recruiting

  • West GTA Research Inc.

    Mississauga, Ontario, Canada · Active not recruiting

  • TIDHI Innovation Inc.

    Toronto, Ontario, Canada · Recruiting

  • McGill University Health Center

    Montreal, Quebec, Canada · Recruiting

  • Amsterdam UMC

    Amsterdam, Netherlands · Active not recruiting

  • Erasmus University Medical Center

    Holland, Netherlands · Active not recruiting

  • Waikato Hospital

    Hamilton, New Zealand · Active not recruiting

  • Capital Coast and Hutt

    Lower Hutt, New Zealand · Recruiting

  • Aotearoa Clinical Trials

    Papatoetoe, Auckland, New Zealand · Recruiting

  • Universitätsspital Zürich

    Zurich, Switzerland · Recruiting

  • Cardiff and Vale University Health Board-Wales

    Cardiff, United Kingdom · Recruiting

  • Royal Liverpool University Hospital

    Liverpool, United Kingdom · Active not recruiting

  • St George's University of London

    London, United Kingdom · Recruiting

  • Cambridge University Hospitals NHS Foundation Trust

    Cambridge, Cambridgeshire, United Kingdom · Recruiting

  • Norfolk and Norwich University Hospital

    Norwich, Norfolk, United Kingdom · Recruiting

  • Belfast Trust

    Belfast, Northern Ireland, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.